John F. Resek, Ph.D., is a partner in Nelson Mullins Riley & Scarborough’s Boston office where he practices intellectual property law primarily in the areas of pharmaceuticals, chemistry, biochemistry, and chemical-biology.

Dr. Resek became interested in pursuing a career in patent law while working in industry as a drug-discovery scientist in the area of diabetes care.  By that time he had extensive training in organic and medicinal chemistry, pharmacology, biochemistry, and chemical biology.  He earned his Ph.D. in Biochemical Pharmacology from the University of Wisconsin studying the biochemistry of drug-receptor interaction. He was a post-doctoral fellow at M.I.T. where he studied chemical-biology with Nobel Laureate H. Gobind Khorana. He was the author/co-author on several scientific research articles and reviews on signal transduction and chemical biology published in journals such as Biochemistry, The Journal of Biological Chemistry, The Journal of Organic Chemistry and The Proceedings of the National Academy of Sciences. His drug-discovery work resulted in two issued U.S. patents.

Dr. Resek graduated from Fordham Law School in 2001.  He is a U.S. Registered Patent Attorney and is admitted to practice in New York and New Jersey.  He has more than 10 years experience in client counseling, patent procurement, drafting opinions, and due diligence evaluations with a particular focus on organic and medicinal chemistry, chemical synthesis, process chemistry, the solid state chemistry of drugs, pharmaceutical formulations, signal-transduction, metabolism, protein structure and function, vaccine development and chemical biology. Dr. Resek is experienced at advising clients on Hatch-Waxman issues. He is also skilled in bringing complex patent interference matters before the U.S. Patent and Trademark Office.

Over the course of his career Dr. Resek has:

• developed patent portfolios for nutraceutical and pharmaceutical clients;
• performed due diligences evaluations on privately held pharmaceutical companies for investment banks;
• opined on numerous patent claims for non-infringement and invalidity positions;
• been involved in several interferences in which he developed and implemented strategies that allowed his pharmaceutical clients to successfully resolve the interferences in their favor.

 Representative Cases

• U.S. Patent No. 7,504,419, Diastereomers of 4-aryloxy-3-hydroxypiperidines.
• U.S. Patent No. 6,784,209, Food supplement for increasing lean mass and strength.
• McNamara v. Pritchard, Interference No. 105,654.
• Moyle v. Grootenhuis, Interference No. 105,600.
• Himmelsbach v. Bradbury, Interference Nos. 105,595 and 105,596.
• Li et al. v. Singer et al., Interference No. 105,366.
• Byrn et al. v. Aronhime et al., Interference No. 105,384.
• Danishefsky v. Hoefle, Interference No. 105,298.